Share Price and Basic Stock Data
Last Updated: February 10, 2026, 9:42 pm
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Vadivarhe Speciality Chemicals Ltd operates within the specialty chemicals sector, focusing on diverse chemical products. The company’s sales figures exhibited significant fluctuations over the years, with a reported ₹28.58 Cr in FY 2020, dropping to ₹21.45 Cr in FY 2022, before rebounding to ₹43.68 Cr in FY 2023. This recovery indicates a positive trend, with trailing twelve months (TTM) sales standing at ₹40.48 Cr. Quarterly sales data from March 2020 to September 2023 showed variability, with a peak of ₹22.32 Cr in March 2023, but a decline to ₹14.10 Cr in September 2023. The company’s sales trajectory reflects an ability to leverage market opportunities but also highlights the volatility inherent in the specialty chemicals market. The significant increase in sales to ₹25.98 Cr in March 2024 suggests a rebound, yet the subsequent decline to ₹14.47 Cr in September 2024 raises concerns about sustainability. Overall, Vadivarhe’s revenue performance underscores both recovery potential and market challenges.
Profitability and Efficiency Metrics
Profitability remains a critical concern for Vadivarhe Speciality Chemicals Ltd, with operating profit margins (OPM) fluctuating significantly. The OPM stood at -14.44% as of September 2025, indicating ongoing challenges in managing operational costs. The company reported a net profit of ₹0.98 Cr in March 2023, transitioning back into losses in subsequent periods, with a net profit of -₹3.75 Cr in September 2023 and -₹3.30 Cr in September 2024. The interest coverage ratio (ICR) was recorded at -4.63x, reflecting difficulty in covering interest expenses. The return on equity (ROE) was remarkably high at 495%, suggesting effective capital utilization, albeit against a backdrop of negative profitability. Vadivarhe’s cash conversion cycle (CCC) of 108.78 days indicates a longer time taken to convert investments into cash flows, signaling inefficiencies in inventory management. Overall, while there are signs of operational recovery, profitability metrics remain a critical area of concern.
Balance Sheet Strength and Financial Ratios
The balance sheet of Vadivarhe Speciality Chemicals Ltd reflects significant financial strain, particularly with total borrowings amounting to ₹31.37 Cr against reserves of -₹19.41 Cr as of September 2025. This negative reserve position indicates accumulated losses that could affect future financing and operational flexibility. The current ratio stood at 0.89x, suggesting potential liquidity issues, as it is below the ideal benchmark of 1.0x. The debt-to-equity ratio was recorded at -12.98x, indicating a precarious capital structure heavily reliant on debt financing. Additionally, the company’s price-to-book value ratio (P/BV) of -12.09x highlights market concerns regarding asset valuation. The enterprise value (EV) of ₹69.02 Cr further emphasizes the market’s perception of the company’s financial health. These metrics collectively indicate a need for strategic financial restructuring and improved capital management to stabilize operations.
Shareholding Pattern and Investor Confidence
Vadivarhe Speciality Chemicals Ltd’s shareholding structure reveals a significant concentration of ownership, with promoters holding 66.83% as of September 2025, while the public holds 33.17%. This concentration can lead to potential governance issues, impacting minority shareholder interests. The number of shareholders increased from 340 in December 2022 to 448 by September 2025, indicating a growing interest from the investing public despite the company’s financial challenges. The gradual decline in promoter shareholding from 74.64% in December 2022 to 66.83% in September 2025 may signal a potential shift towards increasing public participation. Investor confidence may be tested due to the company’s inconsistent profitability and negative equity reserves, which could deter new investments. Overall, while the increasing number of shareholders suggests interest, the concentrated promoter holding may raise concerns about governance and decision-making processes.
Outlook, Risks, and Final Insight
Looking ahead, Vadivarhe Speciality Chemicals Ltd faces a mixed outlook characterized by both opportunities and risks. The potential for revenue recovery is evident, particularly if the company successfully navigates operational efficiencies and improves profitability metrics. However, the persistent negative net profit and substantial debt burden pose significant risks. The volatility in sales and profitability, as reflected in historical data, suggests that the company must address its operational challenges proactively. Risks include potential liquidity constraints due to a low current ratio and negative reserves, which could limit growth opportunities. Conversely, effective management of operational costs and strategic financial restructuring could enhance long-term viability. In conclusion, while Vadivarhe holds potential for recovery, its financial health requires careful navigation of existing challenges to realize sustainable growth.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| HP Adhesives Ltd | 381 Cr. | 41.5 | 65.4/35.0 | 23.7 | 20.5 | 0.96 % | 13.6 % | 9.82 % | 2.00 |
| Haryana Leather Chemicals Ltd | 31.0 Cr. | 63.2 | 88.8/52.0 | 14.8 | 89.6 | 1.58 % | 8.02 % | 5.45 % | 10.0 |
| Hardcastle & Waud Mfg Co Ltd | 49.5 Cr. | 728 | 899/600 | 16.7 | 697 | 0.00 % | 6.31 % | 2.91 % | 10.0 |
| Grauer & Weil (India) Ltd | 3,300 Cr. | 72.8 | 111/68.2 | 21.8 | 22.0 | 0.69 % | 23.3 % | 17.6 % | 1.00 |
| DMCC Speciality Chemicals Ltd | 610 Cr. | 243 | 373/208 | 23.3 | 93.8 | 1.03 % | 14.1 % | 9.97 % | 10.0 |
| Industry Average | 13,082.72 Cr | 748.00 | 59.13 | 182.97 | 0.45% | 12.99% | 25.41% | 6.41 |
Quarterly Result
| Metric | Mar 2020 | Sep 2020 | Mar 2021 | Sep 2021 | Mar 2022 | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 12.02 | 13.85 | 12.62 | 9.82 | 11.63 | 21.36 | 22.32 | 14.10 | 25.98 | 14.47 | 23.44 | 17.04 |
| Expenses | 16.73 | 14.32 | 12.78 | 12.39 | 15.98 | 19.80 | 20.58 | 15.01 | 21.04 | 16.41 | 27.92 | 19.50 |
| Operating Profit | -4.71 | -0.47 | -0.16 | -2.57 | -4.35 | 1.56 | 1.74 | -0.91 | 4.94 | -1.94 | -4.48 | -2.46 |
| OPM % | -39.18% | -3.39% | -1.27% | -26.17% | -37.40% | 7.30% | 7.80% | -6.45% | 19.01% | -13.41% | -19.11% | -14.44% |
| Other Income | 0.27 | 0.90 | 0.18 | 0.33 | 0.34 | 0.28 | 0.82 | 0.19 | 0.30 | 0.11 | 0.22 | 0.28 |
| Interest | 0.67 | 0.59 | 0.64 | 0.87 | 0.70 | 0.78 | 0.69 | 0.71 | 0.57 | 0.58 | 0.75 | 0.73 |
| Depreciation | 0.82 | 0.90 | 0.91 | 0.91 | 0.88 | 0.89 | 0.89 | 0.87 | 0.86 | 0.89 | 0.95 | 0.95 |
| Profit before tax | -5.93 | -1.06 | -1.53 | -4.02 | -5.59 | 0.17 | 0.98 | -2.30 | 3.81 | -3.30 | -5.96 | -3.86 |
| Tax % | -32.38% | 0.00% | 11.11% | 0.00% | 0.00% | 0.00% | 0.00% | 63.04% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit | -4.01 | -1.06 | -1.70 | -4.01 | -5.59 | 0.17 | 0.98 | -3.75 | 3.81 | -3.30 | -5.96 | -3.85 |
| EPS in Rs | -3.14 | -0.83 | -1.33 | -3.14 | -4.37 | 0.13 | 0.77 | -2.93 | 2.98 | -2.58 | -4.66 | -3.01 |
Last Updated: December 28, 2025, 3:32 pm
Below is a detailed analysis of the quarterly data for Vadivarhe Speciality Chemicals Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 17.04 Cr.. The value appears to be declining and may need further review. It has decreased from 23.44 Cr. (Mar 2025) to 17.04 Cr., marking a decrease of 6.40 Cr..
- For Expenses, as of Sep 2025, the value is 19.50 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 27.92 Cr. (Mar 2025) to 19.50 Cr., marking a decrease of 8.42 Cr..
- For Operating Profit, as of Sep 2025, the value is -2.46 Cr.. The value appears strong and on an upward trend. It has increased from -4.48 Cr. (Mar 2025) to -2.46 Cr., marking an increase of 2.02 Cr..
- For OPM %, as of Sep 2025, the value is -14.44%. The value appears strong and on an upward trend. It has increased from -19.11% (Mar 2025) to -14.44%, marking an increase of 4.67%.
- For Other Income, as of Sep 2025, the value is 0.28 Cr.. The value appears strong and on an upward trend. It has increased from 0.22 Cr. (Mar 2025) to 0.28 Cr., marking an increase of 0.06 Cr..
- For Interest, as of Sep 2025, the value is 0.73 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.75 Cr. (Mar 2025) to 0.73 Cr., marking a decrease of 0.02 Cr..
- For Depreciation, as of Sep 2025, the value is 0.95 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.95 Cr..
- For Profit before tax, as of Sep 2025, the value is -3.86 Cr.. The value appears strong and on an upward trend. It has increased from -5.96 Cr. (Mar 2025) to -3.86 Cr., marking an increase of 2.10 Cr..
- For Tax %, as of Sep 2025, the value is 0.00%. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00%.
- For Net Profit, as of Sep 2025, the value is -3.85 Cr.. The value appears strong and on an upward trend. It has increased from -5.96 Cr. (Mar 2025) to -3.85 Cr., marking an increase of 2.11 Cr..
- For EPS in Rs, as of Sep 2025, the value is -3.01. The value appears strong and on an upward trend. It has increased from -4.66 (Mar 2025) to -3.01, marking an increase of 1.65.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 4:26 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 13.87 | 19.03 | 26.28 | 35.03 | 25.56 | 32.36 | 28.58 | 26.47 | 21.45 | 43.68 | 40.08 | 37.91 | 40.48 |
| Expenses | 11.18 | 11.52 | 18.89 | 24.64 | 21.80 | 29.97 | 37.82 | 27.01 | 28.24 | 40.22 | 35.48 | 43.80 | 47.42 |
| Operating Profit | 2.69 | 7.51 | 7.39 | 10.39 | 3.76 | 2.39 | -9.24 | -0.54 | -6.79 | 3.46 | 4.60 | -5.89 | -6.94 |
| OPM % | 19.39% | 39.46% | 28.12% | 29.66% | 14.71% | 7.39% | -32.33% | -2.04% | -31.66% | 7.92% | 11.48% | -15.54% | -17.14% |
| Other Income | 0.11 | 0.11 | 0.14 | 1.05 | 0.45 | 0.40 | 0.37 | 1.08 | 0.66 | 1.09 | 0.47 | 0.19 | 0.50 |
| Interest | 1.02 | 0.89 | 1.21 | 0.85 | 0.77 | 1.11 | 1.37 | 1.32 | 1.69 | 1.61 | 1.83 | 1.72 | 1.48 |
| Depreciation | 1.65 | 1.09 | 1.36 | 1.14 | 1.27 | 1.63 | 1.75 | 1.81 | 1.79 | 1.79 | 1.74 | 1.85 | 1.90 |
| Profit before tax | 0.13 | 5.64 | 4.96 | 9.45 | 2.17 | 0.05 | -11.99 | -2.59 | -9.61 | 1.15 | 1.50 | -9.27 | -9.82 |
| Tax % | 46.15% | 29.61% | 13.51% | 36.51% | 18.43% | -20.00% | -17.93% | 6.56% | 0.00% | 0.00% | 96.67% | 0.00% | |
| Net Profit | 0.07 | 3.98 | 4.29 | 6.01 | 1.77 | 0.06 | -9.84 | -2.76 | -9.61 | 1.15 | 0.06 | -9.27 | -9.81 |
| EPS in Rs | 1.45 | 82.27 | 88.67 | 4.97 | 1.38 | 0.05 | -7.70 | -2.16 | -7.52 | 0.90 | 0.05 | -7.25 | -7.67 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 5585.71% | 7.79% | 40.09% | -70.55% | -96.61% | -16500.00% | 71.95% | -248.19% | 111.97% | -94.78% | -15550.00% |
| Change in YoY Net Profit Growth (%) | 0.00% | -5577.93% | 32.30% | -110.64% | -26.06% | -16403.39% | 16571.95% | -320.14% | 360.16% | -206.75% | -15455.22% |
Vadivarhe Speciality Chemicals Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 6% |
| 3 Years: | 21% |
| TTM: | -5% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 1% |
| 3 Years: | 2% |
| TTM: | -11763% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 34% |
| 3 Years: | 5% |
| 1 Year: | -54% |
| Return on Equity | |
|---|---|
| 10 Years: | -13% |
| 5 Years: | -54% |
| 3 Years: | -60% |
| Last Year: | -503% |
Last Updated: September 5, 2025, 1:50 pm
Balance Sheet
Last Updated: December 4, 2025, 2:11 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 4.84 | 4.84 | 4.84 | 12.09 | 12.78 | 12.78 | 12.78 | 12.78 | 12.78 | 12.78 | 12.78 | 12.78 | 12.78 |
| Reserves | 5.73 | 9.68 | 12.62 | 11.38 | 14.64 | 14.70 | 4.87 | 2.11 | -7.50 | -6.36 | -6.29 | -15.56 | -19.41 |
| Borrowings | 14.35 | 11.24 | 10.65 | 12.74 | 9.66 | 20.98 | 19.67 | 23.45 | 24.42 | 26.94 | 26.18 | 36.03 | 31.37 |
| Other Liabilities | 7.75 | 3.67 | 5.09 | 9.52 | 7.13 | 9.28 | 14.00 | 8.84 | 11.97 | 13.08 | 8.94 | 9.48 | 14.01 |
| Total Liabilities | 32.67 | 29.43 | 33.20 | 45.73 | 44.21 | 57.74 | 51.32 | 47.18 | 41.67 | 46.44 | 41.61 | 42.73 | 38.75 |
| Fixed Assets | 15.93 | 15.02 | 13.96 | 17.12 | 19.68 | 26.09 | 25.20 | 25.98 | 24.32 | 23.36 | 21.59 | 22.43 | 21.55 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.09 | 1.58 | 1.88 | 2.81 | 0.33 | 1.09 | 0.99 | 1.56 | 0.08 | 0.11 |
| Investments | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 |
| Other Assets | 16.69 | 14.36 | 19.19 | 28.47 | 22.90 | 29.72 | 23.26 | 20.82 | 16.21 | 22.04 | 18.41 | 20.17 | 17.04 |
| Total Assets | 32.67 | 29.43 | 33.20 | 45.73 | 44.21 | 57.74 | 51.32 | 47.18 | 41.67 | 46.44 | 41.61 | 42.73 | 38.75 |
Below is a detailed analysis of the balance sheet data for Vadivarhe Speciality Chemicals Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 12.78 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 12.78 Cr..
- For Reserves, as of Sep 2025, the value is -19.41 Cr.. The value appears to be worsening (becoming more negative). It has deteriorated from -15.56 Cr. (Mar 2025) to -19.41 Cr., marking a decline of 3.85 Cr..
- For Borrowings, as of Sep 2025, the value is 31.37 Cr.. The value appears to be improving (decreasing). However, Reserves are negative, which is a major warning sign. It has decreased from 36.03 Cr. (Mar 2025) to 31.37 Cr., marking a decrease of 4.66 Cr..
- For Other Liabilities, as of Sep 2025, the value is 14.01 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 9.48 Cr. (Mar 2025) to 14.01 Cr., marking an increase of 4.53 Cr..
- For Total Liabilities, as of Sep 2025, the value is 38.75 Cr.. The value appears to be improving (decreasing). It has decreased from 42.73 Cr. (Mar 2025) to 38.75 Cr., marking a decrease of 3.98 Cr..
- For Fixed Assets, as of Sep 2025, the value is 21.55 Cr.. The value appears to be declining and may need further review. It has decreased from 22.43 Cr. (Mar 2025) to 21.55 Cr., marking a decrease of 0.88 Cr..
- For CWIP, as of Sep 2025, the value is 0.11 Cr.. The value appears strong and on an upward trend. It has increased from 0.08 Cr. (Mar 2025) to 0.11 Cr., marking an increase of 0.03 Cr..
- For Investments, as of Sep 2025, the value is 0.05 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.05 Cr..
- For Other Assets, as of Sep 2025, the value is 17.04 Cr.. The value appears to be declining and may need further review. It has decreased from 20.17 Cr. (Mar 2025) to 17.04 Cr., marking a decrease of 3.13 Cr..
- For Total Assets, as of Sep 2025, the value is 38.75 Cr.. The value appears to be declining and may need further review. It has decreased from 42.73 Cr. (Mar 2025) to 38.75 Cr., marking a decrease of 3.98 Cr..
However, the Borrowings (31.37 Cr.) are higher than the Reserves (-19.41 Cr.), which may signal higher financial risk.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -11.66 | -3.73 | -3.26 | -2.35 | -5.90 | -18.59 | -28.91 | -23.99 | -31.21 | -23.48 | -21.58 | -41.92 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 135.00 | 70.97 | 117.50 | 159.63 | 122.95 | 143.25 | 104.34 | 125.62 | 34.37 | 48.22 | 44.99 | 79.53 |
| Inventory Days | 223.98 | 221.86 | 116.68 | 61.66 | 170.63 | 221.62 | 122.32 | 77.40 | 168.42 | 120.82 | 147.37 | 128.08 |
| Days Payable | 128.58 | 50.10 | 108.01 | 115.85 | 120.38 | 174.61 | 205.42 | 152.95 | 218.56 | 145.63 | 122.81 | 98.83 |
| Cash Conversion Cycle | 230.40 | 242.73 | 126.18 | 105.44 | 173.20 | 190.26 | 21.24 | 50.07 | -15.76 | 23.40 | 69.55 | 108.78 |
| Working Capital Days | -31.58 | 16.30 | 43.06 | 63.14 | 85.54 | 90.35 | -30.65 | 11.45 | -106.86 | -33.09 | 15.39 | -27.83 |
| ROCE % | 4.41% | 25.77% | 22.61% | 29.66% | 7.86% | 2.88% | -25.06% | -5.34% | -24.02% | 7.61% | 10.15% | -22.66% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | -7.25 | 0.05 | 1.00 | -8.00 | -2.16 |
| Diluted EPS (Rs.) | -7.25 | 0.05 | 1.00 | -8.00 | -2.16 |
| Cash EPS (Rs.) | -5.80 | 1.41 | 2.30 | -6.12 | -0.74 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | -2.17 | 5.08 | 5.03 | 4.13 | 11.65 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | -2.17 | 5.08 | 5.03 | 4.13 | 11.65 |
| Revenue From Operations / Share (Rs.) | 29.65 | 31.35 | 34.17 | 16.78 | 20.71 |
| PBDIT / Share (Rs.) | -4.81 | 3.54 | 3.16 | -5.09 | -0.23 |
| PBIT / Share (Rs.) | -6.25 | 2.18 | 1.76 | -6.49 | -1.65 |
| PBT / Share (Rs.) | -7.25 | 1.18 | 0.89 | -7.52 | -2.03 |
| Net Profit / Share (Rs.) | -7.25 | 0.04 | 0.89 | -7.52 | -2.16 |
| PBDIT Margin (%) | -16.21 | 11.29 | 9.23 | -30.30 | -1.13 |
| PBIT Margin (%) | -21.09 | 6.96 | 5.14 | -38.65 | -7.95 |
| PBT Margin (%) | -24.44 | 3.76 | 2.62 | -44.79 | -9.78 |
| Net Profit Margin (%) | -24.44 | 0.15 | 2.62 | -44.79 | -10.42 |
| Return on Networth / Equity (%) | 0.00 | 0.94 | 17.84 | -181.94 | -18.54 |
| Return on Capital Employeed (%) | -38.97 | 10.81 | 9.72 | -37.93 | -7.01 |
| Return On Assets (%) | -21.68 | 0.14 | 2.47 | -23.05 | -5.85 |
| Long Term Debt / Equity (X) | -8.22 | 2.91 | 2.53 | 3.01 | 0.97 |
| Total Debt / Equity (X) | -12.98 | 4.03 | 4.19 | 3.75 | 1.29 |
| Asset Turnover Ratio (%) | 0.89 | 0.91 | 0.99 | 0.48 | 0.53 |
| Current Ratio (X) | 0.89 | 1.14 | 0.86 | 0.72 | 1.11 |
| Quick Ratio (X) | 0.45 | 0.59 | 0.49 | 0.38 | 0.91 |
| Inventory Turnover Ratio (X) | 4.14 | 2.59 | 3.35 | 3.69 | 2.54 |
| Interest Coverage Ratio (X) | -4.63 | 3.52 | 2.74 | -4.14 | -0.24 |
| Interest Coverage Ratio (Post Tax) (X) | -6.02 | 1.05 | 1.53 | -5.27 | -1.84 |
| Enterprise Value (Cr.) | 69.02 | 65.29 | 61.35 | 50.97 | 34.38 |
| EV / Net Operating Revenue (X) | 1.82 | 1.63 | 1.40 | 2.38 | 1.30 |
| EV / EBITDA (X) | -11.23 | 14.42 | 15.20 | -7.84 | -114.95 |
| MarketCap / Net Operating Revenue (X) | 0.88 | 0.98 | 0.80 | 1.49 | 0.60 |
| Price / BV (X) | -12.09 | 6.11 | 5.48 | 6.05 | 1.08 |
| Price / Net Operating Revenue (X) | 0.88 | 0.98 | 0.80 | 1.49 | 0.60 |
| EarningsYield | -0.27 | 0.00 | 0.03 | -0.30 | -0.17 |
After reviewing the key financial ratios for Vadivarhe Speciality Chemicals Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is -7.25. This value is below the healthy minimum of 5. It has decreased from 0.05 (Mar 24) to -7.25, marking a decrease of 7.30.
- For Diluted EPS (Rs.), as of Mar 25, the value is -7.25. This value is below the healthy minimum of 5. It has decreased from 0.05 (Mar 24) to -7.25, marking a decrease of 7.30.
- For Cash EPS (Rs.), as of Mar 25, the value is -5.80. This value is below the healthy minimum of 3. It has decreased from 1.41 (Mar 24) to -5.80, marking a decrease of 7.21.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is -2.17. It has decreased from 5.08 (Mar 24) to -2.17, marking a decrease of 7.25.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is -2.17. It has decreased from 5.08 (Mar 24) to -2.17, marking a decrease of 7.25.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 29.65. It has decreased from 31.35 (Mar 24) to 29.65, marking a decrease of 1.70.
- For PBDIT / Share (Rs.), as of Mar 25, the value is -4.81. This value is below the healthy minimum of 2. It has decreased from 3.54 (Mar 24) to -4.81, marking a decrease of 8.35.
- For PBIT / Share (Rs.), as of Mar 25, the value is -6.25. This value is below the healthy minimum of 0. It has decreased from 2.18 (Mar 24) to -6.25, marking a decrease of 8.43.
- For PBT / Share (Rs.), as of Mar 25, the value is -7.25. This value is below the healthy minimum of 0. It has decreased from 1.18 (Mar 24) to -7.25, marking a decrease of 8.43.
- For Net Profit / Share (Rs.), as of Mar 25, the value is -7.25. This value is below the healthy minimum of 2. It has decreased from 0.04 (Mar 24) to -7.25, marking a decrease of 7.29.
- For PBDIT Margin (%), as of Mar 25, the value is -16.21. This value is below the healthy minimum of 10. It has decreased from 11.29 (Mar 24) to -16.21, marking a decrease of 27.50.
- For PBIT Margin (%), as of Mar 25, the value is -21.09. This value is below the healthy minimum of 10. It has decreased from 6.96 (Mar 24) to -21.09, marking a decrease of 28.05.
- For PBT Margin (%), as of Mar 25, the value is -24.44. This value is below the healthy minimum of 10. It has decreased from 3.76 (Mar 24) to -24.44, marking a decrease of 28.20.
- For Net Profit Margin (%), as of Mar 25, the value is -24.44. This value is below the healthy minimum of 5. It has decreased from 0.15 (Mar 24) to -24.44, marking a decrease of 24.59.
- For Return on Networth / Equity (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 15. It has decreased from 0.94 (Mar 24) to 0.00, marking a decrease of 0.94.
- For Return on Capital Employeed (%), as of Mar 25, the value is -38.97. This value is below the healthy minimum of 10. It has decreased from 10.81 (Mar 24) to -38.97, marking a decrease of 49.78.
- For Return On Assets (%), as of Mar 25, the value is -21.68. This value is below the healthy minimum of 5. It has decreased from 0.14 (Mar 24) to -21.68, marking a decrease of 21.82.
- For Long Term Debt / Equity (X), as of Mar 25, the value is -8.22. This value is below the healthy minimum of 0.2. It has decreased from 2.91 (Mar 24) to -8.22, marking a decrease of 11.13.
- For Total Debt / Equity (X), as of Mar 25, the value is -12.98. This value is within the healthy range. It has decreased from 4.03 (Mar 24) to -12.98, marking a decrease of 17.01.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.89. It has decreased from 0.91 (Mar 24) to 0.89, marking a decrease of 0.02.
- For Current Ratio (X), as of Mar 25, the value is 0.89. This value is below the healthy minimum of 1.5. It has decreased from 1.14 (Mar 24) to 0.89, marking a decrease of 0.25.
- For Quick Ratio (X), as of Mar 25, the value is 0.45. This value is below the healthy minimum of 1. It has decreased from 0.59 (Mar 24) to 0.45, marking a decrease of 0.14.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 4.14. This value is within the healthy range. It has increased from 2.59 (Mar 24) to 4.14, marking an increase of 1.55.
- For Interest Coverage Ratio (X), as of Mar 25, the value is -4.63. This value is below the healthy minimum of 3. It has decreased from 3.52 (Mar 24) to -4.63, marking a decrease of 8.15.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is -6.02. This value is below the healthy minimum of 3. It has decreased from 1.05 (Mar 24) to -6.02, marking a decrease of 7.07.
- For Enterprise Value (Cr.), as of Mar 25, the value is 69.02. It has increased from 65.29 (Mar 24) to 69.02, marking an increase of 3.73.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.82. This value is within the healthy range. It has increased from 1.63 (Mar 24) to 1.82, marking an increase of 0.19.
- For EV / EBITDA (X), as of Mar 25, the value is -11.23. This value is below the healthy minimum of 5. It has decreased from 14.42 (Mar 24) to -11.23, marking a decrease of 25.65.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.88. This value is below the healthy minimum of 1. It has decreased from 0.98 (Mar 24) to 0.88, marking a decrease of 0.10.
- For Price / BV (X), as of Mar 25, the value is -12.09. This value is below the healthy minimum of 1. It has decreased from 6.11 (Mar 24) to -12.09, marking a decrease of 18.20.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.88. This value is below the healthy minimum of 1. It has decreased from 0.98 (Mar 24) to 0.88, marking a decrease of 0.10.
- For EarningsYield, as of Mar 25, the value is -0.27. This value is below the healthy minimum of 5. It has decreased from 0.00 (Mar 24) to -0.27, marking a decrease of 0.27.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Vadivarhe Speciality Chemicals Ltd:
- Net Profit Margin: -24.44%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: -38.97% (Industry Average ROCE: 12.99%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 0% (Industry Average ROE: 25.41%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): -6.02
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.45
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 59.13)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: -12.98
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: -24.44%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Chemicals - Speciality - Others | Gat No. 204, Nashik-Mumbai Highway, Nasik Maharashtra 422403 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Sunil Haripant Pophale | Chairman & Executive Director |
| Mrs. Meena Sunil Pophale | Whole Time Director |
| Mr. Prasanna Prabhakar Rege | Independent Director |
| Mr. Ravindra Keshav Paranjpe | Independent Director |
| Mrs. Uttara Adwait Kher | Independent Director |
FAQ
What is the intrinsic value of Vadivarhe Speciality Chemicals Ltd?
Vadivarhe Speciality Chemicals Ltd's intrinsic value (as of 10 February 2026) is ₹305.78 which is 1289.91% higher the current market price of ₹22.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's ₹28.1 Cr. market cap, FY2025-2026 high/low of ₹37.6/16.0, reserves of ₹-19.41 Cr, and liabilities of ₹38.75 Cr.
What is the Market Cap of Vadivarhe Speciality Chemicals Ltd?
The Market Cap of Vadivarhe Speciality Chemicals Ltd is 28.1 Cr..
What is the current Stock Price of Vadivarhe Speciality Chemicals Ltd as on 10 February 2026?
The current stock price of Vadivarhe Speciality Chemicals Ltd as on 10 February 2026 is ₹22.0.
What is the High / Low of Vadivarhe Speciality Chemicals Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Vadivarhe Speciality Chemicals Ltd stocks is ₹37.6/16.0.
What is the Stock P/E of Vadivarhe Speciality Chemicals Ltd?
The Stock P/E of Vadivarhe Speciality Chemicals Ltd is .
What is the Book Value of Vadivarhe Speciality Chemicals Ltd?
The Book Value of Vadivarhe Speciality Chemicals Ltd is 5.19.
What is the Dividend Yield of Vadivarhe Speciality Chemicals Ltd?
The Dividend Yield of Vadivarhe Speciality Chemicals Ltd is 0.00 %.
What is the ROCE of Vadivarhe Speciality Chemicals Ltd?
The ROCE of Vadivarhe Speciality Chemicals Ltd is 22.7 %.
What is the ROE of Vadivarhe Speciality Chemicals Ltd?
The ROE of Vadivarhe Speciality Chemicals Ltd is 495 %.
What is the Face Value of Vadivarhe Speciality Chemicals Ltd?
The Face Value of Vadivarhe Speciality Chemicals Ltd is 10.0.